Merck and Daiichi Sankyo withdraw BLA for ifinatamab deruxtecan in ES-SCLC

Withdrawal is based on FDA discussions; the companies said phase 2 data do not satisfy approval requirements. Enrollment continues in the IDEATE-LUNG02 phase 3 trial, and two additional phase 3 trials are underway.